A citation-based method for searching scientific literature

Yuki Okada, Qin Feng, Yihui Lin, Qi Jiang, Yaqiang Li, Vernon M Coffield, Lishan Su, Guoliang Xu, Yi Zhang. Cell 2005
Times Cited: 564







List of co-cited articles
1330 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor.
Scott R Daigle, Edward J Olhava, Carly A Therkelsen, Christina R Majer, Christopher J Sneeringer, Jeffrey Song, L Danielle Johnston, Margaret Porter Scott, Jesse J Smith, Yonghong Xiao,[...]. Cancer Cell 2011
626
46

MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L.
Kathrin M Bernt, Nan Zhu, Amit U Sinha, Sridhar Vempati, Joerg Faber, Andrei V Krivtsov, Zhaohui Feng, Natalie Punt, Amanda Daigle, Lars Bullinger,[...]. Cancer Cell 2011
569
46

Potent inhibition of DOT1L as treatment of MLL-fusion leukemia.
Scott R Daigle, Edward J Olhava, Carly A Therkelsen, Aravind Basavapathruni, Lei Jin, P Ann Boriack-Sjodin, Christina J Allain, Christine R Klaus, Alejandra Raimondi, Margaret Porter Scott,[...]. Blood 2013
434
44

Methylation of H3-lysine 79 is mediated by a new family of HMTases without a SET domain.
Qin Feng, Hengbin Wang, Huck Hui Ng, Hediye Erdjument-Bromage, Paul Tempst, Kevin Struhl, Yi Zhang. Curr Biol 2002
545
39

H3K79 methylation profiles define murine and human MLL-AF4 leukemias.
Andrei V Krivtsov, Zhaohui Feng, Madeleine E Lemieux, Joerg Faber, Sridhar Vempati, Amit U Sinha, Xiaobo Xia, Jonathan Jesneck, Adrian P Bracken, Lewis B Silverman,[...]. Cancer Cell 2008
377
32

DOT1L inhibits SIRT1-mediated epigenetic silencing to maintain leukemic gene expression in MLL-rearranged leukemia.
Chun-Wei Chen, Richard P Koche, Amit U Sinha, Aniruddha J Deshpande, Nan Zhu, Rowena Eng, John G Doench, Haiming Xu, Scott H Chu, Jun Qi,[...]. Nat Med 2015
132
28

DOT1L/KMT4 recruitment and H3K79 methylation are ubiquitously coupled with gene transcription in mammalian cells.
David J Steger, Martina I Lefterova, Lei Ying, Aaron J Stonestrom, Michael Schupp, David Zhuo, Adam L Vakoc, Ja-Eun Kim, Junjie Chen, Mitchell A Lazar,[...]. Mol Cell Biol 2008
307
26

The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia.
Eytan M Stein, Guillermo Garcia-Manero, David A Rizzieri, Raoul Tibes, Jesus G Berdeja, Michael R Savona, Mojca Jongen-Lavrenic, Jessica K Altman, Blythe Thomson, Stephen J Blakemore,[...]. Blood 2018
159
26

MLL translocations, histone modifications and leukaemia stem-cell development.
Andrei V Krivtsov, Scott A Armstrong. Nat Rev Cancer 2007
769
25

The MLL recombinome of acute leukemias in 2017.
C Meyer, T Burmeister, D Gröger, G Tsaur, L Fechina, A Renneville, R Sutton, N C Venn, M Emerenciano, M S Pombo-de-Oliveira,[...]. Leukemia 2018
265
25

Linking H3K79 trimethylation to Wnt signaling through a novel Dot1-containing complex (DotCom).
Man Mohan, Hans-Martin Herz, Yoh-Hei Takahashi, Chengqi Lin, Ka Chun Lai, Ying Zhang, Michael P Washburn, Laurence Florens, Ali Shilatifard. Genes Dev 2010
199
24

A role for the MLL fusion partner ENL in transcriptional elongation and chromatin modification.
Dorothee Mueller, Christian Bach, Deniz Zeisig, Maria-Paz Garcia-Cuellar, Sara Monroe, Arun Sreekumar, Rong Zhou, Alexey Nesvizhskii, Arul Chinnaiyan, Jay L Hess,[...]. Blood 2007
270
23

AF10 regulates progressive H3K79 methylation and HOX gene expression in diverse AML subtypes.
Aniruddha J Deshpande, Anagha Deshpande, Amit U Sinha, Liying Chen, Jenny Chang, Ali Cihan, Maurizio Fazio, Chun-Wei Chen, Nan Zhu, Richard Koche,[...]. Cancer Cell 2014
103
22

DOT1L, the H3K79 methyltransferase, is required for MLL-AF9-mediated leukemogenesis.
Anh Tram Nguyen, Olena Taranova, Jin He, Yi Zhang. Blood 2011
172
21

Requirement for Dot1l in murine postnatal hematopoiesis and leukemogenesis by MLL translocation.
Stephanie Y Jo, Eric M Granowicz, Ivan Maillard, Dafydd Thomas, Jay L Hess. Blood 2011
144
20

The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis.
Akihiko Yokoyama, Tim C P Somervaille, Kevin S Smith, Orit Rozenblatt-Rosen, Matthew Meyerson, Michael L Cleary. Cell 2005
361
20

Pharmacologic inhibition of the Menin-MLL interaction blocks progression of MLL leukemia in vivo.
Dmitry Borkin, Shihan He, Hongzhi Miao, Katarzyna Kempinska, Jonathan Pollock, Jennifer Chase, Trupta Purohit, Bhavna Malik, Ting Zhao, Jingya Wang,[...]. Cancer Cell 2015
185
20


A higher-order complex containing AF4 and ENL family proteins with P-TEFb facilitates oncogenic and physiologic MLL-dependent transcription.
Akihiko Yokoyama, Min Lin, Alpana Naresh, Issay Kitabayashi, Michael L Cleary. Cancer Cell 2010
244
18

Histone H3 lysine 79 methyltransferase Dot1 is required for immortalization by MLL oncogenes.
Ming-Jin Chang, Hongyu Wu, Nicholas J Achille, Mary Rose Reisenauer, Chau-Wen Chou, Nancy J Zeleznik-Le, Charles S Hemenway, Wenzheng Zhang. Cancer Res 2010
120
17

MLL targets SET domain methyltransferase activity to Hox gene promoters.
Thomas A Milne, Scott D Briggs, Hugh W Brock, Mary Ellen Martin, Denise Gibbs, C David Allis, Jay L Hess. Mol Cell 2002
769
17

The histone H3K79 methyltransferase Dot1L is essential for mammalian development and heterochromatin structure.
Brendan Jones, Hui Su, Audesh Bhat, Hong Lei, Jeffrey Bajko, Sarah Hevi, Gretchen A Baltus, Shilpa Kadam, Huili Zhai, Reginald Valdez,[...]. PLoS Genet 2008
228
17


AFF4, a component of the ELL/P-TEFb elongation complex and a shared subunit of MLL chimeras, can link transcription elongation to leukemia.
Chengqi Lin, Edwin R Smith, Hidehisa Takahashi, Ka Chun Lai, Skylar Martin-Brown, Laurence Florens, Michael P Washburn, Joan W Conaway, Ronald C Conaway, Ali Shilatifard. Mol Cell 2010
383
16


Dot1p modulates silencing in yeast by methylation of the nucleosome core.
Fred van Leeuwen, Philip R Gafken, Daniel E Gottschling. Cell 2002
601
16

Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia.
Mark A Dawson, Rab K Prinjha, Antje Dittmann, George Giotopoulos, Marcus Bantscheff, Wai-In Chan, Samuel C Robson, Chun-wa Chung, Carsten Hopf, Mikhail M Savitski,[...]. Nature 2011
15

Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia.
Jolanta Grembecka, Shihan He, Aibin Shi, Trupta Purohit, Andrew G Muntean, Roderick J Sorenson, Hollis D Showalter, Marcelo J Murai, Amalia M Belcher, Thomas Hartley,[...]. Nat Chem Biol 2012
239
15

AF9 YEATS domain links histone acetylation to DOT1L-mediated H3K79 methylation.
Yuanyuan Li, Hong Wen, Yuanxin Xi, Kaori Tanaka, Haibo Wang, Danni Peng, Yongfeng Ren, Qihuang Jin, Sharon Y R Dent, Wei Li,[...]. Cell 2014
190
15

The MLL recombinome of acute leukemias in 2013.
C Meyer, J Hofmann, T Burmeister, D Gröger, T S Park, M Emerenciano, M Pombo de Oliveira, A Renneville, P Villarese, E Macintyre,[...]. Leukemia 2013
296
14

The diverse functions of Dot1 and H3K79 methylation.
Anh Tram Nguyen, Yi Zhang. Genes Dev 2011
351
14

RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia.
Johannes Zuber, Junwei Shi, Eric Wang, Amy R Rappaport, Harald Herrmann, Edward A Sison, Daniel Magoon, Jun Qi, Katharina Blatt, Mark Wunderlich,[...]. Nature 2011
14

Catalytic site remodelling of the DOT1L methyltransferase by selective inhibitors.
Wenyu Yu, Emma J Chory, Amy K Wernimont, Wolfram Tempel, Alex Scopton, Alexander Federation, Jason J Marineau, Jun Qi, Dalia Barsyte-Lovejoy, Joanna Yi,[...]. Nat Commun 2012
176
14

Leukemic transformation by the MLL-AF6 fusion oncogene requires the H3K79 methyltransferase Dot1l.
Aniruddha J Deshpande, Liying Chen, Maurizio Fazio, Amit U Sinha, Kathrin M Bernt, Deepti Banka, Stuart Dias, Jenny Chang, Edward J Olhava, Scott R Daigle,[...]. Blood 2013
114
14

MLL-Rearranged Leukemias-An Update on Science and Clinical Approaches.
Amanda C Winters, Kathrin M Bernt. Front Pediatr 2017
171
14

The PZP Domain of AF10 Senses Unmodified H3K27 to Regulate DOT1L-Mediated Methylation of H3K79.
Shoudeng Chen, Ze Yang, Alex W Wilkinson, Aniruddha J Deshpande, Simone Sidoli, Krzysztof Krajewski, Brian D Strahl, Benjamin A Garcia, Scott A Armstrong, Dinshaw J Patel,[...]. Mol Cell 2015
51
27

Transcription control by the ENL YEATS domain in acute leukaemia.
Michael A Erb, Thomas G Scott, Bin E Li, Huafeng Xie, Joshiawa Paulk, Hyuk-Soo Seo, Amanda Souza, Justin M Roberts, Shiva Dastjerdi, Dennis L Buckley,[...]. Nature 2017
124
14

The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells.
William J Harris, Xu Huang, James T Lynch, Gary J Spencer, James R Hitchin, Yaoyong Li, Filippo Ciceri, Julian G Blaser, Brigit F Greystoke, Allan M Jordan,[...]. Cancer Cell 2012
378
13

Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9.
Andrei V Krivtsov, David Twomey, Zhaohui Feng, Matthew C Stubbs, Yingzi Wang, Joerg Faber, Jason E Levine, Jing Wang, William C Hahn, D Gary Gilliland,[...]. Nature 2006
999
13

DOT1L inhibitor EPZ-5676 displays synergistic antiproliferative activity in combination with standard of care drugs and hypomethylating agents in MLL-rearranged leukemia cells.
Christine R Klaus, Dorothy Iwanowicz, Danielle Johnston, Carly A Campbell, Jesse J Smith, Mikel P Moyer, Robert A Copeland, Edward J Olhava, Margaret Porter Scott, Roy M Pollock,[...]. J Pharmacol Exp Ther 2014
74
17

Complementary activities of DOT1L and Menin inhibitors in MLL-rearranged leukemia.
C Dafflon, V J Craig, H Méreau, J Gräsel, B Schacher Engstler, G Hoffman, F Nigsch, S Gaulis, L Barys, M Ito,[...]. Leukemia 2017
45
28

Degree of recruitment of DOT1L to MLL-AF9 defines level of H3K79 Di- and tri-methylation on target genes and transformation potential.
Aravinda Kuntimaddi, Nicholas J Achille, Jeremy Thorpe, Alyson A Lokken, Ritambhara Singh, Charles S Hemenway, Mazhar Adli, Nancy J Zeleznik-Le, John H Bushweller. Cell Rep 2015
62
20

ENL links histone acetylation to oncogenic gene expression in acute myeloid leukaemia.
Liling Wan, Hong Wen, Yuanyuan Li, Jie Lyu, Yuanxin Xi, Takayuki Hoshii, Julia K Joseph, Xiaolu Wang, Yong-Hwee E Loh, Michael A Erb,[...]. Nature 2017
101
13

Selective inhibition of tumor oncogenes by disruption of super-enhancers.
Jakob Lovén, Heather A Hoke, Charles Y Lin, Ashley Lau, David A Orlando, Christopher R Vakoc, James E Bradner, Tong Ihn Lee, Richard A Young. Cell 2013
12

MLL-AF4 Spreading Identifies Binding Sites that Are Distinct from Super-Enhancers and that Govern Sensitivity to DOT1L Inhibition in Leukemia.
Jon Kerry, Laura Godfrey, Emmanouela Repapi, Marta Tapia, Neil P Blackledge, Helen Ma, Erica Ballabio, Sorcha O'Byrne, Frida Ponthan, Olaf Heidenreich,[...]. Cell Rep 2017
39
30

Abrogation of MLL-AF10 and CALM-AF10-mediated transformation through genetic inactivation or pharmacological inhibition of the H3K79 methyltransferase Dot1l.
L Chen, A J Deshpande, D Banka, K M Bernt, S Dias, C Buske, E J Olhava, S R Daigle, V M Richon, R M Pollock,[...]. Leukemia 2013
96
12

Disruptor of telomeric silencing-1 is a chromatin-specific histone H3 methyltransferase.
Nicolas Lacoste, Rhea T Utley, Joanna M Hunter, Guy G Poirier, Jacques Côte. J Biol Chem 2002
212
12

Targeting Chromatin Regulators Inhibits Leukemogenic Gene Expression in NPM1 Mutant Leukemia.
Michael W M Kühn, Evelyn Song, Zhaohui Feng, Amit Sinha, Chun-Wei Chen, Aniruddha J Deshpande, Monica Cusan, Noushin Farnoud, Annalisa Mupo, Carolyn Grove,[...]. Cancer Discov 2016
84
13

Polycomb repressive complex 2 is required for MLL-AF9 leukemia.
Tobias Neff, Amit U Sinha, Michael J Kluk, Nan Zhu, Mohamed H Khattab, Lauren Stein, Huafeng Xie, Stuart H Orkin, Scott A Armstrong. Proc Natl Acad Sci U S A 2012
152
11

Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia.
Timothy J Ley, Christopher Miller, Li Ding, Benjamin J Raphael, Andrew J Mungall, A Gordon Robertson, Katherine Hoadley, Timothy J Triche, Peter W Laird, Jack D Baty,[...]. N Engl J Med 2013
11


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.